Literature DB >> 26334620

Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.

Riccardo Piagnerelli1, Daniele Marrelli2,3, Giandomenico Roviello4, Francesco Ferrara5, Giulio Di Mare5, Costantino Voglino5, Roberto Petrioli6, Mario Marini7, Raffaele Macchiarelli7, Franco Roviello1.   

Abstract

CA 19-9 is a marker correlated to the clinical evolution of pancreatic adenocarcinoma. To analyze the clinical value of pre- and postoperative CA 19-9 serum levels in stage I and II pancreatic cancer. We analyzed 61 patients resected for pancreatic cancer. Patients were evaluated about the pre-operative CA 19-9 values and then divided into 3 groups: high, high-low and low, on the basis of pre- and postoperative CA 19-9 levels. The correlations between these groups and age, sex, pT, pN, tumor stage, jaundice, surgical radicality, tumor size, number of harvested and positive lymph nodes, grading, overall and major morbidities and post-operative mortality together with survival rates were analyzed. Higher values of pre-operative CA 19-9 were significantly correlated to the presence of jaundice, high pT, pN, stage and higher number of metastatic lymph nodes. In 49 patients (80.3 %) an R0 resection was performed. Five-year overall survival (OS) and disease free survival (DFS) were significantly better in patients with high levels of pre-operative CA 19-9, even in R0 cases. After stratification, 30 patients were included in the high group, 13 in the high-low group and 18 in the low group. A statistically significant correlation was found between the CA 19-9 groups and the lymph nodal positivity, not between CA 19-9 and pT. OS and DFS were significantly better in low group patients. We confirm the prognostic value of preoperative CA 19-9 serum levels. We do not support early postoperative modifications of CA19-9 as an adjunctive prognostic variable.

Entities:  

Keywords:  CA 19-9; Pancreatic cancer; Pancreatic resection; Prognostic factors

Mesh:

Substances:

Year:  2015        PMID: 26334620     DOI: 10.1007/s13277-015-3986-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

Authors:  Naru Kondo; Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Ryutaro Sakabe; Norifumi Shigemoto; Yasushi Kato; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

2.  Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.

Authors:  Teiichi Sugiura; Katsuhiko Uesaka; Hideyuki Kanemoto; Takashi Mizuno; Keiko Sasaki; Hiroyoshi Furukawa; Kazuya Matsunaga; Atsuyuki Maeda
Journal:  J Gastrointest Surg       Date:  2012-03-13       Impact factor: 3.452

Review 3.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

4.  Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer.

Authors:  Gary Y Yang; Nadia K Malik; Rameela Chandrasekhar; Wen-Wee Ma; Leayn Flaherty; Renuka Iyer; Boris Kuvshinoff; John Gibbs; Gregory Wilding; Graham Warren; Kilian Salerno May
Journal:  J Gastrointest Oncol       Date:  2013-12

5.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

6.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

Review 7.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Authors:  M J Duffy; C Sturgeon; R Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann
Journal:  Ann Oncol       Date:  2009-08-18       Impact factor: 32.976

8.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

9.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

10.  Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.

Authors:  Adam C Berger; Miguel Garcia; John P Hoffman; William F Regine; Ross A Abrams; Howard Safran; Andre Konski; Alan B Benson; John MacDonald; Christopher G Willett
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

View more
  6 in total

1.  The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.

Authors:  Jayabal Pandiaraja; Subramanian Viswanathan; Thomas Babu Antomy; Sathyamoorthy Thirumuruganand; Dhandapani Subramanian Kumaresan
Journal:  J Clin Diagn Res       Date:  2016-03-01

2.  Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Luis Bujanda
Journal:  Ann Transl Med       Date:  2016-02

3.  Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway.

Authors:  Xiaoyu Li; Yi Liu; Cuiping Zhang; Qinghui Niu; Hui Wang; Cong Che; Man Xie; Bin Zhou; Yonghong Xu; Qi Zhang; Jun Wu; Zibin Tian
Journal:  Oncotarget       Date:  2017-03-07

Review 4.  Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Morgan Bonds; Flavio G Rocha
Journal:  J Clin Med       Date:  2019-08-12       Impact factor: 4.241

5.  Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.

Authors:  Casper van Eijck; Stefan Löb; Friedrich Anger; Anna Döring; Jacob van Dam; Johan Friso Lock; Ingo Klein; Max Bittrich; Christoph-Thomas Germer; Armin Wiegering; Volker Kunzmann
Journal:  Ann Surg Oncol       Date:  2020-09-12       Impact factor: 5.344

6.  Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9.

Authors:  Roman O Kowalchuk; Scott C Lester; Rondell P Graham; William S Harmsen; Lizhi Zhang; Thorvardur R Halfdanarson; Rory L Smoot; Hunter C Gits; Wen Wee Ma; Dawn Owen; Amit Mahipal; Robert C Miller; Michelle A Neben Wittich; Sean P Cleary; Robert R McWilliams; Michael G Haddock; Christopher L Hallemeier; Mark J Truty; Kenneth W Merrell
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.